OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma

被引：2
|
作者：
Todaro, Maria [1 ,2 ]
Boi, Michela [1 ,2 ]
Vurchio, Valentina [1 ,2 ]
Ercole, Elisabetta [1 ,2 ]
Machiorlatti, Rodolfo [1 ,2 ]
Messana, Katia [1 ,2 ]
Landra, Indira [1 ,2 ]
Urigu, Susanna [1 ,2 ]
Aliberti, Sabrina [1 ,2 ]
Riveiro, Eugenia [3 ]
Bertoni, Francesco [4 ]
Inghirami, Giorgio [5 ]
机构：
[1] Univ Turin, Dept Pathol, Turin, Italy
[2] Univ Turin, Ctr Expt Res & Med Studies CeRMS, Turin, Italy
[3] Oncol Therapeut Dev, Clichy, France
[4] Oncol Res Inst, Bellinzona, Switzerland
[5] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-5531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5531
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
    Boi, Michela
    Gaudio, Eugenio
    Bonetti, Paola
    Kwee, Ivo
    Bernasconi, Elena
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Cascione, Luciano
    Ponzoni, Maurilio
    Mensah, Afua Adjeiwaa
    Stathis, Anastasios
    Stussi, Georg
    Riveiro, Maria Eugenia
    Herait, Patrice
    Inghirami, Giorgio
    Cvitkovic, Esteban
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1628 - 1638
  • [32] BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN-amplified neuroblastoma
    Schulte, Johannes H.
    Althoff, Kristina
    Bell, Emma
    Odersky, Andrea
    Beckers, Anneleen
    Speleman, Frank
    Schaefers, Simon
    Schramm, Alexander
    Eggert, Angelika
    Westermann, Frank
    Riveiro, Eugenia
    Cvitkovic, Esteban
    Henssen, Anton
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [33] The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma
    Maser, Tyler
    Zagorski, Joseph
    Kelly, Shannon
    Ostrander, Anna
    Goodyke, Austin
    Nagulapally, Abhinav
    Bond, Jeffrey
    Park, Yeonhee
    Saulnier Sholler, Giselle
    [J]. CANCER MEDICINE, 2020, 9 (21): : 8144 - 8158
  • [34] BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
    Coude, Marie-Magdelaine
    Braun, Thorsten
    Berrou, Jeannig
    Dupont, Melanie
    Bertrand, Sibyl
    Masse, Aline
    Raffoux, Emmanuel
    Itzykson, Raphael
    Delord, Marc
    Riveiro, Maria E.
    Herait, Patrice
    Baruchel, Andre
    Dombret, Herve
    Gardin, Claude
    [J]. ONCOTARGET, 2015, 6 (19) : 17698 - 17712
  • [35] OTX015, a novel BET-BRD inhibitor is active in non-small-cell lung cancer cell (NSCLC) lines harboring different oncogenic mutations
    Riveiro, M.
    Astorgues-Xerri, L.
    Ijaz, N.
    Bekradda, M.
    Vazquez, R.
    Frapolli, R.
    Rinaldi, A.
    Kwee, I.
    Cvitkovic, E.
    Raymond, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 182 - 182
  • [36] Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias
    Braun, Thorsten
    Coude, Marie Magdelaine
    Berrou, Jeannig
    Bertrand, Sibyl
    Riveiro, Eugenia
    Herait, Patrice
    Baruchel, Andre
    Dombret, Herve
    Gardin, Claude
    [J]. BLOOD, 2013, 122 (21)
  • [37] DOSE OPTIMIZATION OF MK-8628 (OTX015), A SMALL MOLECULE INHIBITOR OF BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Hottinger, A. F.
    Sanson, M.
    Moyal, E.
    Delord, J.
    Rezai, K.
    Leung, A.
    Perez, S.
    Bekradda, M.
    Lachaux, N.
    Chinot, O.
    [J]. NEURO-ONCOLOGY, 2016, 18 : 56 - 56
  • [38] Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation
    Riveiro, Maria Eugenia
    Astorgues-Xerri, Lucile
    Canet-jourdan, Charlotte
    Bekradda, Mohamed
    Cvitkovic, Esteban
    Herait, Patrice
    Raymond, Eric
    [J]. BLOOD, 2014, 124 (21)
  • [39] The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors
    Gaudio, Eugenio
    Bernasconi, Elena
    Kwee, Ivo
    Boi, Michela
    Bonetti, Paola
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Ponzoni, Maurilio
    Stathis, Anastasios
    Stuessi, Georg
    Riveiro, Eugenia
    Herait, Patrice
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [40] Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
    Elodie Odore
    François Lokiec
    Esteban Cvitkovic
    Mohamed Bekradda
    Patrice Herait
    Fabrice Bourdel
    Carmen Kahatt
    Emmanuel Raffoux
    Anastasios Stathis
    Catherine Thieblemont
    Bruno Quesnel
    David Cunningham
    Maria E. Riveiro
    Keyvan Rezaï
    [J]. Clinical Pharmacokinetics, 2016, 55 : 397 - 405
12345